Company / SG&A Expense
iBio, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$11.7M
FY2025
5-year range
$11.4M / $22.0M
FY2021-FY2025
Trend
-38.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has declined for 3 consecutive years, from $22M in FY2022 to $12M in FY2025.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of -1.1%.
Improved from $22M to $12M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -19.1%
- 5-Year CAGR
- -1.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- iBio, Inc.'s sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of -1.1%, indicating a declining trend.
- In FY2025, sg&a expense decreased 38.6% year-over-year.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.36 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.7M | -38.6% |
| FY2024 | $19.0M | -12.6% |
| FY2023 | $21.8M | -1.3% |
| FY2022 | $22.0M | +93.8% |
| FY2021 | $11.4M | -7.8% |
| FY2020 | $12.3M | +15.4% |
| FY2019 | $10.7M | +1.3% |
| FY2018 | $10.6M | +37.3% |
| FY2017 | $7.7M | +53.0% |
| FY2016 | $5.0M | +29.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026